Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis

Dermatologica. 1988;177(4):218-24. doi: 10.1159/000248567.

Abstract

A randomized double-blind study was designed with 65 patients in order to clarify two points: (1) does addition of a retinoid to psoralen-ultra violet A photochemotherapy (PUVA) of severe psoriasis decrease the UVA energy required to achieve remission, and (2) is there a difference between two retinoids, i.e. etretinate and acitretin. Acitretin-PUVA treatment was significantly superior to placebo-PUVA with respect to several items (decrease in lesional scores after 6 weeks of therapy, number of PUVA exposures, and total dose of UVA until remission). There were also differences between the etretinate-PUVA and placebo-PUVA groups, but only the decrease in lesional scores reached statistical significance.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Acitretin
  • Adult
  • Clinical Trials as Topic
  • Double-Blind Method
  • Etretinate / adverse effects
  • Etretinate / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • PUVA Therapy*
  • Psoriasis / drug therapy*
  • Psoriasis / pathology
  • Random Allocation
  • Remission Induction
  • Tretinoin / adverse effects
  • Tretinoin / analogs & derivatives*
  • Tretinoin / therapeutic use

Substances

  • Tretinoin
  • Etretinate
  • Acitretin